| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a compound of the formula n n n n or a pharmaceutically acceptable salt thereof, wherein X is O or S; R 1 is hydroxyhalogen, (C 1 -C 6 )alkyl, halogen(C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, cyclo(C 3 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halogen(C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl, cyano, (R 6 ) 2 N-(C=O)-, (C 1 -C 6 )alkyl-S-, or furanyl; R 2 is H or (C 1 -C 6 )alkyl; R 3 is H, (C 1 -C 6 )alkyl, halogen(C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl; R 4 is H or (C 1 -C 2 )alkyl; R 5 is H, hydroxy, halogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy; R 6 is H; or R 1 and R 2 form rings together with carbon atoms, to which they are attached, a fused 6- or 7-membered saturated or unsaturated carbocyclic ring. The invention also relates to a pharmaceutical composition based on a compound of formula (I). n EFFECT: new isochromane or isothiochromane derivatives, useful as alpha2 adrenoreceptor agonists, have been obtained. n 10 cl, 1 tbl, 106 ex |